Key Points
- CFO Alex Thurman sold 2,511 shares on March 25 at an average price of $106.46 for proceeds of $267,321, reducing his stake by 5.65% to 41,967 shares, per an SEC filing.
- Glaukos reported Q results with EPS of ($0.28), missing estimates by $0.06, while revenue rose 35.6% year‑over‑year to $143.12 million and beat expectations, though the company remains unprofitable with negative margins.
- Shares opened down about 4.3% at $103.13; analysts have a consensus Moderate Buy rating with an average target of $133.69 and price targets ranging as high as $160, reflecting mixed views.
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 2,511 shares of the company's stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total transaction of $267,321.06. Following the completion of the sale, the chief financial officer owned 41,967 shares of the company's stock, valued at approximately $4,467,806.82. This trade represents a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Glaukos Trading Down 4.3%
Shares of GKOS stock opened at $103.13 on Friday. The company has a market capitalization of $5.99 billion, a P/E ratio of -31.63 and a beta of 0.70. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10. The business's 50 day moving average is $112.94 and its two-hundred day moving average is $101.97. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $130.23.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The company had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. During the same period in the prior year, the business earned ($0.40) earnings per share. Glaukos's revenue for the quarter was up 35.6% compared to the same quarter last year. Equities analysts forecast that Glaukos Corporation will post -1.08 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on GKOS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Glaukos in a report on Thursday, January 22nd. The Goldman Sachs Group reiterated a "buy" rating and set a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. Wall Street Zen lowered Glaukos from a "buy" rating to a "hold" rating in a research note on Saturday, February 21st. Needham & Company LLC raised their target price on shares of Glaukos from $125.00 to $127.00 and gave the stock a "buy" rating in a research report on Wednesday, February 18th. Finally, Stifel Nicolaus upped their price target on Glaukos from $115.00 to $160.00 and gave the stock a "buy" rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Glaukos presently has a consensus rating of "Moderate Buy" and an average target price of $133.69.
Get Our Latest Analysis on Glaukos
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in GKOS. UMB Bank n.a. increased its position in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 158 shares during the last quarter. First Horizon Corp grew its stake in Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Glaukos in the fourth quarter valued at about $28,000. Larson Financial Group LLC raised its stake in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 132 shares in the last quarter. Finally, REAP Financial Group LLC bought a new position in Glaukos during the 3rd quarter worth approximately $40,000. 99.04% of the stock is owned by institutional investors and hedge funds.
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
